BIOMAT Database Logo BIOMAT Database Logo

Considerations on thyrotoxicosis treatment with antithyroid drugs. 1962

S NEMETH

UI MeSH Term Description Entries
D006980 Hyperthyroidism Hypersecretion of THYROID HORMONES from the THYROID GLAND. Elevated levels of thyroid hormones increase BASAL METABOLIC RATE. Hyperthyroid,Primary Hyperthyroidism,Hyperthyroidism, Primary,Hyperthyroids
D013956 Antithyroid Agents Agents that are used to treat hyperthyroidism by reducing the excessive production of thyroid hormones. Antithyroid Agent,Antithyroid Drug,Goitrogen,Goitrogens,Thyroid Antagonists,Antithyroid Drugs,Antithyroid Effect,Antithyroid Effects,Agent, Antithyroid,Agents, Antithyroid,Antagonists, Thyroid,Drug, Antithyroid,Drugs, Antithyroid,Effect, Antithyroid,Effects, Antithyroid
D013971 Thyrotoxicosis A hypermetabolic syndrome caused by excess THYROID HORMONES which may come from endogenous or exogenous sources. The endogenous source of hormone may be thyroid HYPERPLASIA; THYROID NEOPLASMS; or hormone-producing extrathyroidal tissue. Thyrotoxicosis is characterized by NERVOUSNESS; TACHYCARDIA; FATIGUE; WEIGHT LOSS; heat intolerance; and excessive SWEATING. Thyrotoxicoses
D018931 Antineoplastic Agents, Hormonal Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) Hormonal Antineoplastic Agents,Antineoplastic Drugs, Hormonal,Antineoplastic Hormonal Agents,Antineoplastic Hormonal Drugs,Antineoplastics, Hormonal,Hormonal Agents, Antineoplastic,Hormonal Antineoplastic Drugs,Hormonal Antineoplastics,Agents, Antineoplastic Hormonal,Drugs, Antineoplastic Hormonal,Hormonal Drugs, Antineoplastic

Related Publications

S NEMETH
Treatment of thyrotoxicosis with antithyroid drugs.
August 1948, Revue medicale de Liege,
S NEMETH
[Long-term treatment of thyrotoxicosis with antithyroid drugs].
March 1970, Nordisk medicin,
S NEMETH
Thyrotoxicosis and antithyroid drugs.
June 1998, Postgraduate medical journal,
S NEMETH
Thyrotoxicosis and antithyroid drugs.
June 1997, Postgraduate medical journal,
S NEMETH
IODINE DEFICIENCY AFTER TREATMENT OF THYROTOXICOSIS WITH ANTITHYROID DRUGS.
September 1964, Lancet (London, England),
S NEMETH
[Therapy of thyrotoxicosis with antithyroid drugs].
February 1968, Lakartidningen,
S NEMETH
Iodine organification defect following treatment of thyrotoxicosis with antithyroid drugs.
July 1975, Clinical endocrinology,
S NEMETH
Thyrotoxicosis in pregnancy: results of treatment by antithyroid drugs combined with T4.
January 1983, Clinical endocrinology,
S NEMETH
Recurrence of thyrotoxicosis with regard to thyroid suppressibility after treatment with antithyroid drugs.
January 1973, Acta endocrinologica. Supplementum,
S NEMETH
Five-year follow-up of thyrotoxicosis treated with antithyroid drugs.
September 1974, Endokrinologie,
Copied contents to your clipboard!